Literature DB >> 28078640

Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods.

Kavitha Nutakki1, James W Varni2,3, Sheila Steinbrenner4, Claire B Draucker4, Nancy L Swigonski5,6.   

Abstract

Health-related quality of life (HRQOL) is arguably one of the most important measures in evaluating effectiveness of clinical treatments. At present, there is no disease-specific outcome measure to assess the HRQOL of children, adolescents and young adults with Neurofibromatosis Type 1 (NF1). This study aimed to develop the items and support the content validity for the Pediatric Quality of Life Inventory™ (PedsQL™) NF1 Module for children, adolescents and young adults. The iterative process included multiphase qualitative methods including a literature review, survey of expert opinions, semi-structured interviews, cognitive interviews and pilot testing. Fifteen domains were derived from the qualitative methods, with content saturation achieved, resulting in 115 items. The domains include skin, pain, pain impact, pain management, cognitive functioning, speech, fine motor, balance, vision, perceived physical appearance, communication, worry, treatment, medicines and gastrointestinal symptoms. This study is limited because all participants are recruited from a single-site. Qualitative methods support the content validity for the PedsQL™ NF1 Module for children, adolescents and young adults. The PedsQL™ NF1 Module is now undergoing national multisite field testing for the psychometric validation of the instrument development.

Entities:  

Keywords:  Adolescents; Children; Health-related quality of life; Neurofibromatosis type 1; Patient reported outcomes; PedsQL™; Quality of life

Mesh:

Year:  2017        PMID: 28078640     DOI: 10.1007/s11060-016-2351-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  46 in total

1.  Pediatric health-related quality of life: Feasibility, reliability and validity of the PedsQL transplant module.

Authors:  J Weissberg-Benchell; T E Zielinski; S Rodgers; R N Greenley; D Askenazi; S L Goldstein; E M Fredericks; S McDiarmid; L Williams; C A Limbers; K Tuzinkiewicz; S Lerret; E M Alonso; J W Varni
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

Review 2.  Measuring quality of life in clinical trials: a taxonomy and review.

Authors:  G H Guyatt; S J Veldhuyzen Van Zanten; D H Feeny; D L Patrick
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262

3.  PedsQL gastrointestinal symptoms module item development: qualitative methods.

Authors:  James W Varni; Marie T Kay; Christine A Limbers; James P Franciosi; John F Pohl
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-05       Impact factor: 2.839

4.  Validation of an instrument to measure voice-related quality of life (V-RQOL).

Authors:  N D Hogikyan; G Sethuraman
Journal:  J Voice       Date:  1999-12       Impact factor: 2.009

5.  Sampling plan and patient characteristics of the PROMIS pediatrics large-scale survey.

Authors:  Debra E Irwin; Brian D Stucky; David Thissen; Esi Morgan Dewitt; Jin Shei Lai; Karin Yeatts; James W Varni; Darren A DeWalt
Journal:  Qual Life Res       Date:  2010-03-05       Impact factor: 4.147

6.  Validity of quality of life measurement tools--from generic to disease-specific.

Authors:  George A Wells; Anthony S Russell; Boulos Haraoui; Robert Bissonnette; Carl F Ware
Journal:  J Rheumatol Suppl       Date:  2011-11

7.  The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module.

Authors:  James W Varni; Michael Seid; Tara Smith Knight; Tasha Burwinkle; Joy Brown; Ilona S Szer
Journal:  Arthritis Rheum       Date:  2002-03

8.  Development of a vision-targeted health-related quality of life item measure.

Authors:  Sylvia H Paz; Jerry Slotkin; Roberta McKean-Cowdin; Paul Lee; Cynthia Owsley; Susan Vitale; Rohit Varma; Richard Gershon; Ron D Hays
Journal:  Qual Life Res       Date:  2013-03-09       Impact factor: 4.147

Review 9.  Neurofibromatosis type 1.

Authors:  Jacqueline L Anderson; David H Gutmann
Journal:  Handb Clin Neurol       Date:  2015

Review 10.  Clinical and genetic aspects of neurofibromatosis 1.

Authors:  Kimberly Jett; Jan M Friedman
Journal:  Genet Med       Date:  2010-01       Impact factor: 8.822

View more
  5 in total

1.  PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity.

Authors:  Kavitha Nutakki; James W Varni; Nancy L Swigonski
Journal:  J Neurooncol       Date:  2017-12-22       Impact factor: 4.130

2.  Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1.

Authors:  James W Varni; Kavitha Nutakki; Nancy L Swigonski
Journal:  Qual Life Res       Date:  2018-11-21       Impact factor: 4.147

3.  Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.

Authors:  Pamela L Wolters; Ana-Maria Vranceanu; Heather L Thompson; Staci Martin; Vanessa L Merker; Andrea Baldwin; Carolina Barnett; Kimberley S Koetsier; Cynthia M Hingtgen; Christopher J Funes; James H Tonsgard; Elizabeth K Schorry; Taryn Allen; Taylor Smith; Barbara Franklin; Stephanie Reeve
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

4.  A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1.

Authors:  Alice Heaney; Jeanette Wilburn; Shannon Langmead; Jaishri Blakeley; Susan Huson; Carly Jim; Stephen P McKenna
Journal:  SAGE Open Med       Date:  2019-02-11

5.  Outcome measurement instruments for peripheral vascular malformations and an assessment of the measurement properties: a systematic review.

Authors:  Sophie E R Horbach; Amber P M Rongen; Roy G Elbers; Chantal M A M van der Horst; Cecilia A C Prinsen; Phyllis I Spuls
Journal:  Qual Life Res       Date:  2019-09-23       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.